# Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

> **NCT00848848** · PHASE1 · COMPLETED · sponsor: **Seqirus** · enrollment: 450 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Trivalent Influenza Vaccine
- **BIOLOGICAL:** Trivalent Influenza Vaccine + high A
- **BIOLOGICAL:** Trivalent Influenza Vaccine + ¼ dose adjuvant
- **BIOLOGICAL:** Trivalent Influenza Vaccine + high A + ¼ dose adjuvant
- **BIOLOGICAL:** Trivalent Influenza Vaccine + ½ dose adjuvant
- **BIOLOGICAL:** Trivalent Influenza Vaccine + high A + ½ dose adjuvant
- **BIOLOGICAL:** Trivalent Influenza Vaccine + adjuvant
- **BIOLOGICAL:** Trivalent Influenza Vaccine + high A + adjuvant
- **BIOLOGICAL:** Trivalent Influenza Vaccine intradermal dose
- **BIOLOGICAL:** Trivalent Influenza Vaccine + high A intradermal dose

## Key facts

- **NCT ID:** NCT00848848
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2016-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00848848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00848848, "Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00848848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*